Phase 2 Head and Neck Cancer Trial, Recruiting NCT05777824 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT05777824
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old, of any gender
  • People who have been confirmed through a tissue sample (biopsy) to have squamous cell carcinoma of the head and neck
  • People whose cancer is locally advanced, meaning it has grown significantly into nearby tissue or spread to nearby lymph nodes, but has not spread to distant parts of the body
  • People who are generally well enough to carry out daily activities with little or no restriction (this is measured by a standard health scale called ECOG, scored 0 or 1)
  • People who have received induction chemotherapy combined with immunotherapy, followed by surgery as part of their treatment plan
  • People whose life expectancy is at least 6 months
  • People who have no medical reasons preventing them from receiving chemotherapy, immunotherapy, or radiotherapy

Who may not be able to join:

  • People with a history of another cancer (except for early-stage non-melanoma skin cancer or a very early form of cervical cancer called carcinoma in situ)
  • People who have previously received any systemic (whole-body) cancer treatment targeting the same cancer lesions, before the induction chemotherapy and immunotherapy phase
  • People who have previously had radiation therapy to the head and neck area
  • People who have taken high-dose steroid medications (such as more than 10 mg per day of prednisone or an equivalent) or other immune-suppressing drugs within the month before joining the trial (confirm with trial site regarding exceptions for low-dose or inhaled steroids)
  • People who have fluid build-up around the lungs, heart, or abdomen requiring drainage, or who have had such fluid drained for treatment purposes within 2 weeks before joining
  • People with serious existing health conditions, including heart attack history, irregular heartbeat, stroke or other blood vessel conditions affecting the brain, ulcer disease, mental illness, or diabetes that is not well controlled

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Junlin Yi, Doctor, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC

Phone: 15811166516

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 January 2023
Est. completion
30 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov